<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">IMP3 Expression in Borderline Tumors of the Ovary</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Ahmed</forename><surname>El-Balat</surname></persName>
							<email>ahmed.el-balat@kgu.de</email>
							<affiliation key="aff1">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Goethe University Frankfurt</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nicole</forename><surname>Sänger</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Goethe University Frankfurt</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Karn</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Goethe University Frankfurt</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sven</forename><surname>Becker</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Goethe University Frankfurt</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Uwe</forename><surname>Holtrich</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Goethe University Frankfurt</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zelal</forename><surname>Muallem</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charite University Hospital</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ruza</forename><surname>Arsenic</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charite University Hospital</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Goethe University</orgName>
								<address>
									<addrLine>Theodor-Stern-Kai 7</addrLine>
									<postCode>60590</postCode>
									<settlement>Frankfurt, Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">IMP3 Expression in Borderline Tumors of the Ovary</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">63C176E1256B82E998B1137E5412138D</idno>
					<idno type="DOI">10.21873/anticanres.11351</idno>
					<note type="submission">Received November 25, 2016 Revised December 23, 2016 Accepted December 28, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Ovarian cancer</term>
					<term>borderline tumors</term>
					<term>histological subtypes</term>
					<term>prognosis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background/Aim: Borderline ovarian tumors (BOTs) have a less aggressive behavior than invasive epithelial ovarian tumors.</s><s>Still some patients relapse or succumb to disease.</s><s>Molecular markers that reliably predict prognosis are lacking.</s><s>Insulin-like growth factor II mRNA-binding protein (IMP3) has been suggested as a prognostic marker in colorectal, hepatocellular, and ovarian clear-cell carcinomas.</s><s>Materials and Methods: We analyzed the expression of IMP3 by immunohistochemistry in a cohort of 140 BOT and its association with histopathological features.</s><s>Results: We found no association of IMP3 expression with patients' age, FIGO stage, microinvasion, and presence of implants.</s><s>In contrast, IMP3 expression correlated to mucinous subtype of BOTs (42.2% vs. 9.5% among other subtypes) (p&lt;0.001).</s><s>IMP3 expression was found to be associated with the presence of in situ carcinoma in MBOT, but not in other subtypes (p=0.021).</s><s>Conclusion: Expression of IMP3 in BOT is associated with the mucinous subtype and may serve as an early indicator for the development of malignant features.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Borderline ovarian tumors (BOTs) are defined as epithelial tumors with a stratification of epithelial lining, but with no evidence of stromal invasion on pathologic examination.</s><s>They have a less aggressive behavior than invasive epithelial ovarian tumors <ref type="bibr" target="#b0">(1)</ref>.</s><s>They exist in various subtypes, including serous, mucinous (endocervical and intestinal type, of which intestinal type is more common), seromucinous, clear cell, endometrioid and Brenner <ref type="bibr" target="#b1">(2)</ref>.</s><s>Molecular markers that could reliably differentiate between tumors with good or bad prognosis are lacking.</s></p><p><s>Insulin-like growth factor II mRNA-binding protein (IMP3) is involved in embryogenesis and it is rarely expressed in normal adult tissue and benign tumors.</s><s>On the other hand, it has been reported to be expressed in a variety of malignant neoplasms.</s><s>Consequently, IMP3 may act as a novel biomarker that can differentiate normal tissues from cancerous tissues <ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b3">4)</ref> and as already shown as a prognostic marker in colorectal, hepatocellular, and ovarian clear-cell carcinomas <ref type="bibr" target="#b4">(5)</ref><ref type="bibr" target="#b5">(6)</ref><ref type="bibr" target="#b6">(7)</ref>.</s><s>Conflicting results have been reported for epithelial ovarian carcinoma (EOC), in which overexpression of IMP1, but not IMP3, was associated with advanced-stage, high-histological grade and poor survival <ref type="bibr" target="#b7">(8)</ref>.</s><s>For borderline tumors of the ovary there are no data on IMP3 expression yet.</s><s>Hence, the aim of this study was to evaluate the expression of IMP3 in borderline tumors of the ovary and to analyze potential relationships between clinical and pathological characteristics of BOTs and IMP3 expression.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head><p><s>Patients and samples.</s><s>All analyses were performed according to the reporting recommendations for tumour marker prognostic studies (REMARK) <ref type="bibr" target="#b8">(9)</ref>.</s><s>A cohort of 156 borderline tumors of the ovary (BOT) undergoing surgical resection was retrospectively assembled between January 1997 and September 2013 at the Goethe University Hospital in Frankfurt/Main, Germany.</s><s>Formalin-fixed, paraffinembedded (FFPE) tissue samples were obtained from Senckenberg's Institute of Pathology, University Frankfurt (Frankfurt, Germany) and were re-evaluated by a second pathologist at the Institute of Pathology at the Charité Universitätsmedizin Berlin, Germany.</s><s>For 140 of the samples with validated diagnosis sufficient archival material for immunohistochemical analysis was available.</s><s>Pathological characteristics of this cohort are listed in Table <ref type="table" target="#tab_0">I</ref>.</s><s>The Local Research Ethics Committees approved studies of human tissue and samples were processed anonymously.</s></p><p><s>Histopathological evaluation and immunohistochemistry. Routine histopathology sections stained with haematoxylin-eosin were used for diagnosis and second reviewing by experienced pathologists.</s><s>Diagnosis and classification was performed according to the current criteria of the World Health Organization (WHO) <ref type="bibr" target="#b9">(10)</ref>.</s><s>After mounting on Superfrost Plus slides, paraffin sections (2 μm) were dewaxed in xylene and rehydrated to water by a series of graduated ethanol.</s><s>For antigen retrieval, sections were incubated for 20 min in a microwave oven (800 W) using EDTA buffer (10 mmol/l; pH 8.0).</s><s>Monoclonal anti-IMP3 antibody (Cat.#</s><s>M3626, clone 69.1, Lot.# 10085605 Dako, Glostrup, Denmark) was used at a 1:100 dilution.</s><s>Incubation with the antibody for 1 hour at room temperature was performed.</s><s>For negative controls, the primary antibody was omitted.</s><s>For secondary antibody incubation, the Dako REAL Detection System Alkaline Phosphatase/RED (Dako) was applied, following the instructions of the vendor.</s><s>Sections were counterstained with hematoxylin.</s><s>IMP3 were scored semiquantitatively based on the product of staining intensity (SI) and percentage of positively stained cells (PP) as a combined immunoreactive score (CIS): CIS=SI×PP.</s><s>SI was assigned as 0, negative; 1, weak; 2, moderate; or 3, intense.</s><s>PP was defined as 0, none; 1, &lt;25%; 2, 25-50%; 3, 51-75%; or 4, &gt;80% positive stained cells.</s><s>All assessments were made blinded with respect to clinical patient data.</s></p><p><s>Statistical analysis.</s><s>Chi-Square and Fisher's Exact Test were used to determine significance of categorical variables, Mann-Whitney U-Test for the analysis of continuous variables.</s><s>All p-values are two-sided and 0.05 was applied as significance level.</s><s>Subjects with missing values were excluded from the analyses.</s><s>All analyses were performed using SPSS Statistics Version 22 (IBM Corp., New York, NY, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Sample characteristics of the cohort.</s><s>We retrospectively identified 156 cases of borderline tumor of the ovary (BOT) from pathology records.</s><s>For 14 of the samples sufficient archival material was not available for staining, one sample was re-characterized as adenoma of the ovary and for one BOT only material from implants was available leaving a total of 140 BOT samples for analysis with anti-human IMP3 antibody.</s><s>Median age of those 140 patients was 49.5 years (IQR 36.0-64.3).</s><s>Additional sample characteristics are given in Table <ref type="table" target="#tab_0">I</ref>.</s><s>The majority of the samples were either of serous (60.0%,</s><s>SBOT) or mucinous subtype (32.1%,</s><s>MBOT).</s><s>The high frequency of mucinous histology in BOT as compared to EOC has also been described by others <ref type="bibr" target="#b10">(11)</ref>.</s><s>FIGO stage for most of the patients were either IA (30.0%) or IC (37.9%).</s><s>Micropapillary pattern was observed for 22.9% (17.9% partially) and implants were detected among 9.3% of the patients (Table <ref type="table" target="#tab_0">I</ref>).</s></p><p><s>IMP3 expression in borderline tumors of the ovary.</s><s>Next, IMP3 expression was analyzed by immuno-histochemical analysis of tissue samples from all 140 borderline tumors included in Table <ref type="table" target="#tab_0">I</ref>.</s><s>Examples of representative IMP3 staining results are shown in Figure <ref type="figure" target="#fig_0">1</ref>.</s><s>As previously reported, IMP3 is localized to the cytoplasm in BOT <ref type="bibr" target="#b11">(12)</ref>.</s><s>Fibroblasts and endothelial cells were negative for IMP3 expression.</s><s>No expression of IMP3 was observed in non-neoplastic epithelium.</s><s>Intensity of staining and percentage of stained cells were scored separately and integrated as a combined immuno-histochemical score (CIS, see Materials and Methods section).</s><s>First, the distribution of the observed CIS was analyzed among the 140 BOT samples.</s><s>Based on this distribution we stratified samples into three categories as following: no or weak IMP3 expression (CIS 0-9), medium IMP3 expression (CIS 10-19), or strong expression (CIS &gt;19) (Figure <ref type="figure" target="#fig_1">2</ref>).</s><s>This stratification process resulted in 47 (33.6%) negative or weak cases, 65 (46.4%)</s><s>medium and 28 strong (20.0%)</s><s>cases, respectively.</s><s>We then compared this classification with sample characteristics as presented in Table <ref type="table" target="#tab_1">II</ref>.</s><s>We found no strong differences regarding patients' age, FIGO stage, microinvasion and the presence of implants between samples differing in IMP3 expression (Table <ref type="table" target="#tab_1">II</ref>).</s><s>In contrast, IMP3 expression was highly correlated to mucinous subtype of BOTs with 42.2% of samples with mucinous histology showing strong IMP3 expression compared to only 9.5% among other subtypes (p&lt;0.001;</s><s>Table <ref type="table" target="#tab_1">II</ref>).</s><s>Moreover, an inverse association between IMP3 and the presence of micropapillary pattern, was detected.</s><s>All 32 samples with micropapillary pattern or partially micropapillary pattern showed weak or medium (CIS 0-19) staining for IMP3 and none showed strong IMP3 expression (CIS &gt;19) (p=0.002;</s><s>Table <ref type="table" target="#tab_1">II</ref>).</s><s>However, micropapillary pattern is only observed in the serous subtype (SBOT).</s><s>Thus, we also repeated the analysis within the subgroup of SBOT to verify whether the observation was confounded by the association of IMP3 expression with histological subtypes.</s><s>As presented in Table <ref type="table" target="#tab_2">III</ref> within serous subgroup we found no significant association of micropapillary pattern with IMP3 expression (p=0.107;</s><s>Table <ref type="table" target="#tab_2">III</ref>).</s><s>Assuming further confounding of IMP3 expression and sample characteristics through histological subtype all data were reanalyzed after stratification of the samples by subtype.</s><s>No significant differences were observed for age, FIGO stage, microinvasion, and implants.</s><s>However, as shown in Table <ref type="table" target="#tab_3">IV</ref>, IMP3 expression was found to be associated with the presence of in situ carcinoma in mucinous BOT, but not in other subtypes (p=0.021,</s><s>Table <ref type="table" target="#tab_3">IV</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>IMPs are members of a family of RNA-binding proteins comprising of IMP1, IMP2 and IMP3 which have been implicated in mRNA localization, nuclear export, turnover and translational control.</s><s>The oncofetal protein IMP3 (IGF2 mRNA-Binding Protein 3) originally isolated from a pancreatic cancer tumor screen contains 2 functional RNA recognition motifs (RRM) in addition to 4 K Homology (KH) domains, which bind to target mRNA.</s><s>Nielsen et al.</s></p><p><s>(1999) demonstrated that IMP3 protein associates specifically with the 5-prime UTR of IGF2 mRNA, suggesting a role for IMP3 in the physiologic regulation of IGF2 protein production <ref type="bibr" target="#b12">(13)</ref>.</s><s>In vitro studies have shown that IMP3 promotes tumor cell proliferation, adhesion, and invasion <ref type="bibr" target="#b13">(14)</ref>.</s><s>IMPs are primarily expressed during early embryogenesis <ref type="bibr" target="#b12">(13)</ref>, but IMP expression is also associated with a number of malignant neoplasms [reviewed in <ref type="bibr" target="#b14">(15)</ref>].</s></p><p><s>The aim of this study was to evaluate the expression of IMP3 in borderline tumors of the ovary (BOT).</s><s>We studied a cohort of 140 borderline tumors of the ovary, which to our  knowledge represents the largest analysis of IMP3 in BOT up to date.</s><s>The overall composition of our cohort with high prominence of SBOT and MBOT subtypes (64.5% and 31.9%</s><s>respectively) resembled those of large meta-analyses <ref type="bibr" target="#b10">(11)</ref>.</s><s>We found a highly significant association of IMP3 positivity both with mucinous histology (MBOT) and with the presence of intraepithelial carcinoma (p&lt;0.001 and p=0.021, respectively).</s><s>Importantly, even within the MBOT subgroup the correlation of IMP3 with intraepithelial carcinoma is also significant (p=0.044).</s><s>In line with previous studies, strong IMP3 expression was rarely found expressed in SBOT (8.3%), whereas a large portion of MBOT samples (42.2%) displayed a CIS score &gt;19 <ref type="bibr" target="#b11">(12,</ref><ref type="bibr" target="#b15">16)</ref>.</s></p><p><s>In invasive cancers, expression of IMP3 has been shown to correlate with a more aggressive tumor behavior and unfavorable prognosis.</s><s>Köbel et al. assessed IMP3 expression in 475 ovarian carcinomas from a population-based cohort <ref type="bibr" target="#b5">(6)</ref>.</s><s>Disease-specific survival was found to be significantly shorter in patients with IMP3 expressing clear cell carcinomas, whereas no significant difference in disease-specific survival was found for high-grade serous or endometrioid subtypes <ref type="bibr" target="#b5">(6)</ref>.</s><s>Intriguingly, the highest rate of IMP3 expression in the ovarian carcinoma cohort was seen in the mucinous subtype (86%, N=30), followed by clear cell carcinomas and high-grade serous carcinomas <ref type="bibr" target="#b5">(6)</ref>.</s><s>This pattern of IMP3 staining among ovarian carcinoma subtypes is similar to that found in our BOT collection showing highest rates of IMP3 expression in MBOT (42.2%) and only 8.3% in SBOT.</s></p><p><s>Recent studies suggested that Brenner and mucinous tumours originate from microscopic transitional cell nests at the tubal-mesothelial junction <ref type="bibr" target="#b16">(17)</ref>.</s><s>In these tumours, their mucinous component becomes dominant when they grow.</s><s>They compress and eventually obliterate the adjacent ovary giving the appearance that they arose in the ovary <ref type="bibr" target="#b16">(17)</ref>.</s><s>Ovarian mucinous carcinogenesis has been postulated to be a sequential process starting with mucinous cystadenomas ANTICANCER RESEARCH 37: 583-588 (2017) 586 and progress through transitional stages of intraepithelial mucinous carcinoma and micro-invasive mucinous carcinoma, from which mucinous carcinoma develops <ref type="bibr" target="#b17">(18)</ref>.</s><s>Borderline tumors with intraepithelial carcinoma and/or microinvasion provide evidence that these tumors form a morphologic spectrum with individual types representing steps in the sequence of mucinous carcinogenesis in the ovary <ref type="bibr" target="#b18">(19)</ref>.</s><s>In our study we found that all MBOTs with intraepithelial carcinoma (N=5) are characterized by strong IMP3 expression in contrast to only 14/40 (35%) with no intraepithelial carcinoma (p=0.021).</s><s>This difference was not detected among SBOT (p=0.53).</s><s>Thus similar to reports on various human carcinomas the expression of IMP3 in MBOT may also be associated with a more aggressive phenotype of tumor-derived cells <ref type="bibr" target="#b19">(20)</ref>.</s><s>In summary, differential expression of IMP3 in BOT is associated with the mucinous subtype and may serve as an early indicator for the development of malignant features.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Immunohistochemichal detection of IMP3 expression in borderline tumors of the ovary.</s><s>Mucinous borderline (A) and serous tumor (B) of the ovary showing strong cytoplasmic positivity for IMP3.</s><s>Original magnification ×40.</s><s>(C) Mucinous borderline and (D) serous tumor of the ovary showing no positivity for IMP3.</s><s>Original magnification ×40.</s></p></div></figDesc><graphic coords="3,149.55,76.14,303.36,227.52" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Distribution of IMP3 CIS scores in 140 borderline tumors of the ovary.</s><s>Negative/weak IMP3 expression (CIS 0-9): blue; medium IMP3 expression (CIS 10-19): green; strong IMP3 expression (CIS &gt;19): red.</s></p></div></figDesc><graphic coords="3,308.83,367.23,232.56,214.08" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table I .</head><label>I</label><figDesc><div><p><s>Sample characteristics.</s></p></div></figDesc><table><row><cell>Characteristic according second pathology</cell><cell></cell><cell>N</cell><cell>%</cell></row><row><cell>Subtype FIGO stage Implants Micropapillary pattern Presence of in situ carcinoma* Microinvasion</cell><cell>Serous Mucinous Endometroid Mixed IA IB IC II III IV N.A. No Yes No Partially Yes No Yes No Yes</cell><cell>84 45 2 9 42 8 53 7 7 1 22 127 13 108 25 7 121 13 137 3</cell><cell>60.0% 32.1% 1.4% 6.4% 30.0% 5.7% 37.9% 5.0% 5.0% 0.7% 15.7% 90.7% 9.3% 77.1% 17.9% 5.0% 90.7% 9.3% 97.9% 2.1%</cell></row></table><note><p><s>*According to WHO criteria: Cribriform glands measuring 5 mm in one dimension and nuclear atypia greater than that allowed in SBOT.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table II .</head><label>II</label><figDesc><div><p><s>IMP3 expression in borderline tumors of the ovary.</s></p></div></figDesc><table><row><cell>Sample characteristic</cell><cell cols="2">IMP3 negative/weak (CIS=0-9)</cell><cell cols="2">IMP3 medium (CIS 10-19)</cell><cell cols="2">IMP3 strong (CIS&gt;19)</cell><cell>p-Value</cell></row><row><cell>Frequency Median age FIGO stage Subtype Presence of intraepithelial carcinoma No (95% CI) I II III IV N.A. Serous Mucinous Endometroid Mixed Yes Micropapillary pattern No Partially Yes Microinvasion No Yes Implants No Yes</cell><cell>47 49.2 29 1 4 1 12 29 14 1 3 44 3 37 10 0 47 0 41 6</cell><cell>33.6% (43.6-54.8) 23.8% 0.0% 66.7% 100% 57.1% 34.5% 31.1% 50.0% 33.3% 34.6% 23.0% 34.3% 40.0% 0.0% 34.3% 0% 32.0% 50.0%</cell><cell>65 48.5 52 5 2 0 6 48 12 1 4 60 5 43 15 7 63 2 60 5</cell><cell>46.4% (44.3-55.6) 57.1% 80.0% 33.3% 0.0% 28.6% 57.1% 26.7% 50.0% 44.4% 47.2% 38.5% 39.8% 60.0% 100% 46.0% 66.7% 46.9% 41.7%</cell><cell>28 45.9 23 1 0 0 3 7 19 0 2 23 5 28 0 0 27 1 27 1</cell><cell>20.0% (53.1-56.0) 19.0% 20.0% 0.0% 0.0% 14.3% 8.3% 42.2% 50.0% 22.2% 18.1% 38.5% 25.9% 0.0% 0.0% 19.7% 3.6% 21.1% 8.3%</cell><cell>p=0.46 p=0.25 p&lt;0.001 p=0.21 p=0.002 p=0.456 p=0.366</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table III .</head><label>III</label><figDesc><div><p><s>IMP3 expression and micropapillary pattern in SBOT.</s></p></div></figDesc><table><row><cell>Sample characteristic</cell><cell></cell><cell cols="2">IMP3 weak and medium</cell><cell>IMP3 strong</cell><cell></cell><cell>p-Value</cell></row><row><cell>Micropapillary pattern</cell><cell>No Partially Yes</cell><cell>46 24 7</cell><cell>86.8% 100.0% 100.0%</cell><cell>7 0 0</cell><cell>13.2% 0.0% 0.0%</cell><cell>p=0.107</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table IV .</head><label>IV</label><figDesc><div><p><s>IMP3 expression and presence of intraepithelial carcinoma in BOT subtypes.</s></p></div></figDesc><table><row><cell>Sample characteristic</cell><cell>Intraepithelial carcinoma</cell><cell cols="2">IMP3 negative/ weak (CIS=0-9)</cell><cell cols="2">IMP3 medium (CIS 10-19)</cell><cell cols="2">IMP3 strong (CIS&gt;19)</cell><cell>p-Value</cell></row><row><cell>Serous Mucinous Endometroid Mixed</cell><cell>No Yes No Yes No Yes No Yes</cell><cell>28 1 14 0 0 1 2 1</cell><cell>35.4% 20.0% 35.0% 0.0% 0.0% 50.0% 28.6% 100.0%</cell><cell>44 4 12 0 0 1 4 0</cell><cell>55.7% 80.0% 30.0% 0.0% 0.0% 50.0% 57.1% 0.0%</cell><cell>7 0 14 5 0 0 1 0</cell><cell>8.9% 0.0% 35.0% 100.0% 0.0% 0.0% 14.3% 0.0%</cell><cell>p=0.534 p=0.021 N.A. p=0.386</cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The Authors thank Katerina Brinkmann and Samira Adel for expert technical assistance.</s><s>Furthermore, the authors thank Prof. Dr. M.L. Hansmann, Senckenberg's Institute of Pathology, University of Frankfurt, for providing formalin-fixed, paraffin-embedded tissue samples.</s><s>This work was supported by grants from the Margarete Bonifer-Stiftung, Bad Soden, the H.W. &amp; J. Hector-Stiftung, Mannheim (grant number: M67), and the BANSS-Stiftung, Biedenkopf.</s><s>No financial or personal conflict of interest by any of the Authors to declare.</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Malignant and semi-malignant tumors of the ovary</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Taylor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surg Gynecol Obstet</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="204" to="230" />
			<date type="published" when="1929">1929</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Current update on borderline ovarian neoplasms</title>
		<author>
			<persName><forename type="first">N</forename><surname>Lalwani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Shanbhogue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vikram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nagar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jagirdar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Prasad</forename><surname>Sr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="page" from="330" to="336" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Findeis-Hosey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="303" to="314" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Yantiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Woda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Fanger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kalos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Whalen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Andersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rock</forename><surname>Kl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dresser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg Pathol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="188" to="195" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Jeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Kao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Hsu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1118" to="1127" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kobel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Bourne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">O</forename><surname>Spaulding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shih Ie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Soslow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Ewanowich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Kalloger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Huntsman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Gilks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mod Pathol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="469" to="475" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer</title>
		<author>
			<persName><forename type="first">P</forename><surname>Lochhead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Imamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Morikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kuchiba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yamauchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">R</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nishihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Meyerhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Fuchs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ogino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="3405" to="3413" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer</title>
		<author>
			<persName><forename type="first">L</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shigemasa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ohama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="671" to="678" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Statistics Subcommittee of the NCIEWGoCD: Reporting recommendations for tumor marker prognostic studies (REMARK)</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Taube</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Clark</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="1180" to="1184" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">WHO Classification of Tumours of Female Reproductive Organs</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Kurman</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">307</biblScope>
		</imprint>
	</monogr>
	<note>Fourth Edition</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ewald-Riegler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>De Gregorio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Reuss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mahner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fotopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kommoss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schmalfeldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hilpert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fehm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Burges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hillemanns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hanker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hasenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Strauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hellriegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wimberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Keyver-Paik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Canzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wollschlaeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Forner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pfisterer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Schroder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Munstedt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kommoss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hauptmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Arbeitsgmeinschaft Gynakologische Onkologie</forename><surname>Study</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="1905" to="1914" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">IMP3 expression in serous tumors of the ovary</title>
		<author>
			<persName><forename type="first">M</forename><surname>Chiste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alexis</forename><forename type="middle">J</forename><surname>Recine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Appl Immunohistochem Mol Morphol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="658" to="662" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development</title>
		<author>
			<persName><forename type="first">J</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Christiansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lykke-Andersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Johnsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">M</forename><surname>Wewer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Nielsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1262" to="1270" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">RNA-binding IMPs promote cell adhesion and invadopodia formation</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vikesaa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">V</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jonson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Borup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">M</forename><surname>Wewer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Christiansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Nielsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1456" to="1468" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Whiteman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Webb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Australian Ovarian Cancer</forename><surname>Study</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="223" to="230" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">IMP3 expression in human ovarian cancer is associated with improved survival</title>
		<author>
			<persName><forename type="first">A</forename><surname>Noske</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Faggad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wirtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Darb-Esfahani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sehouli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Weichert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Buckendahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roske</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dietel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Denkert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Gynecol Pathol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="203" to="210" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Seidman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Khedmati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Pathol Lab Med</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="1753" to="1760" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Ovarian mucinous borderline tumors of intestinal type without intraepithelial carcinoma: are they still tumors of low malignant potential?</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Aizawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pathol Int</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="420" to="424" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Diagnosis, treatment, and follow-up of borderline ovarian tumors</title>
		<author>
			<persName><forename type="first">D</forename><surname>Fischerova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zikan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dundr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cibula</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1515" to="1533" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lederer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schleifer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Huttelmaier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Cancer Biol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="3" to="12" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
